兆科眼科-B（06622）宣布，其研发的硫酸阿托品滴眼液已正式获得澳大利亚药品管理局（Therapeutic Goods Administration）的审评受理。该产品旨在用于延缓儿童近视进展，此次受理标志着公司在国际化战略布局上迈出重要一步。
作为眼科创新药研发企业，兆科眼科持续深耕近视防控领域。硫酸阿托品滴眼液若最终获批，将有望为澳大利亚市场提供新的近视管理方案。公司表示将积极配合监管机构开展后续审评工作，推动产品早日惠及患者。
兆科眼科-B（06622）宣布，其研发的硫酸阿托品滴眼液已正式获得澳大利亚药品管理局（Therapeutic Goods Administration）的审评受理。该产品旨在用于延缓儿童近视进展，此次受理标志着公司在国际化战略布局上迈出重要一步。
作为眼科创新药研发企业，兆科眼科持续深耕近视防控领域。硫酸阿托品滴眼液若最终获批，将有望为澳大利亚市场提供新的近视管理方案。公司表示将积极配合监管机构开展后续审评工作，推动产品早日惠及患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.